万孚生物
(300482)
| 流通市值：85.61亿 | | | 总市值：121.44亿 |
| 流通股本：3.33亿 | | | 总股本：4.72亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 861,092,255.54 | 2,764,914,157.4 | 2,004,422,655.85 | 1,488,639,716.15 |
| 营业收入 | 861,092,255.54 | 2,764,914,157.4 | 2,004,422,655.85 | 1,488,639,716.15 |
| 二、营业总成本 | 609,782,073.05 | 2,294,651,409.08 | 1,615,373,174.63 | 1,145,868,960.59 |
| 营业成本 | 290,147,748.24 | 1,033,770,911.55 | 744,896,148.13 | 542,550,879.16 |
| 税金及附加 | 3,035,065.86 | 12,169,762.61 | 5,633,079.69 | 4,227,225.83 |
| 销售费用 | 159,814,237.68 | 649,987,779.66 | 465,933,408.93 | 315,503,723.8 |
| 管理费用 | 58,488,722.9 | 227,126,561.28 | 150,734,910.79 | 106,243,827.31 |
| 研发费用 | 105,547,760.15 | 378,001,427.16 | 259,473,251.75 | 190,736,091.8 |
| 财务费用 | -7,251,461.78 | -6,405,033.18 | -11,297,624.66 | -13,392,787.31 |
| 其中:利息费用 | 7,144,336.06 | 29,934,757.58 | 21,492,878.36 | 14,707,118.29 |
| 其中:利息收入 | 5,273,629.58 | 27,612,652.78 | 15,191,469.21 | 9,030,198.82 |
| 加:公允价值变动收益 | 867,577.36 | 14,798,910.67 | 14,232,201.65 | 289,836.51 |
| 加:投资收益 | 2,955,606.08 | 31,099,528.72 | 26,475,961.53 | 22,223,105.63 |
| 资产处置收益 | - | 80,136.83 | -55,222.24 | -55,222.24 |
| 资产减值损失(新) | - | -11,521,801.91 | - | - |
| 信用减值损失(新) | -8,464,136.88 | -1,499,456.3 | -885,393.48 | -1,616,214.49 |
| 其他收益 | 5,603,512.83 | 45,918,052.56 | 33,952,229.65 | 24,604,930.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 252,272,741.88 | 549,138,118.89 | 462,769,258.33 | 388,217,191.05 |
| 加:营业外收入 | 228,831.68 | 3,546,505.31 | 2,119,779.76 | 1,269,961.93 |
| 减:营业外支出 | 897,895.03 | 11,921,965.64 | 5,401,846.36 | 2,888,796.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 251,603,678.53 | 540,762,658.56 | 459,487,191.73 | 386,598,356.42 |
| 减:所得税费用 | 31,160,058.03 | 53,334,297.2 | 61,799,489.51 | 53,774,992.83 |
| 六、净利润 | 220,443,620.5 | 487,428,361.36 | 397,687,702.22 | 332,823,363.59 |
| 持续经营净利润 | 220,443,620.5 | 491,006,240.13 | 397,687,702.22 | 332,823,363.59 |
| 终止经营净利润 | - | -3,577,878.77 | - | - |
| 归属于母公司股东的净利润 | 218,334,248.48 | 487,624,779.55 | 399,811,312.04 | 334,503,325.44 |
| 少数股东损益 | 2,109,372.02 | -196,418.19 | -2,123,609.82 | -1,679,961.85 |
| (一)基本每股收益 | 0.49 | 1.1 | 0.91 | 0.76 |
| (二)稀释每股收益 | 0.49 | 1.1 | 0.91 | 0.76 |
| 八、其他综合收益 | 413,477.28 | -109,988,273.54 | 2,216,813.85 | 1,912,650.31 |
| 归属于母公司股东的其他综合收益 | 413,477.28 | -109,988,273.54 | 2,216,813.85 | 1,912,650.31 |
| 九、综合收益总额 | 220,857,097.78 | 377,440,087.82 | 399,904,516.07 | 334,736,013.9 |
| 归属于母公司股东的综合收益总额 | 218,747,725.76 | 377,636,506.01 | 402,028,125.89 | 336,415,975.75 |
| 归属于少数股东的综合收益总额 | 2,109,372.02 | -196,418.19 | -2,123,609.82 | -1,679,961.85 |
| 公告日期 | 2024-04-22 | 2024-04-22 | 2023-10-26 | 2023-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |